Back

Three decades of secondary prevention in ASCVD: temporal trends in risk factors and recurrent cardiovascular events

28 August 2026 (09:00 - 09:15)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk profiles and secondary prevention Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Elbrich Marieke Wempe

(Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Aggregate risk score based on markers of hepatic steatosis, systemic inflammation, and renal stress to predict MACE across the CKM spectrum
Doctor B. Zhang (Xi'an, CN)
Abstract Slides
Presentation thumbnail
Differences in cardiovascular risk profiles between patients with obstructive coronary artery disease and ANOCA patients with coronary vasomotor dysfunction: insights from two multicentre registries
Ms D. Peeters (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Remnant cholesterol and residual cardiovascular risk in diabetic patients undergoing coronary revascularization: insights from a nationwide ohort
Doctor H. Jeon (Wonju, KR)
Abstract Slides

Access the full session

Session thumbnail
Cardiovascular risk profiles and secondary prevention
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Time trends in risk factor control and use of secondary preventive medication among patients with myocardial infarction attending cardiac rehabilitation: data from the SWEDEHEART registry 2006-2017
30 August 2020
thumbnail
Congress Presentation
Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.
3 September 2019
thumbnail
Congress Presentation
Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study
27 August 2022
thumbnail
Congress Presentation
Cardiovascular risk factors in patients with and without a history of atherosclerotic cardiovascular disease in the SANTORINI study and estimation of risk
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources